Teva to Present at the UBS Global Life Sciences Conference

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the UBS Global Life Sciences Conference with William Marth, President & CEO, Teva Pharmaceuticals - Americas, presenting on Monday, September 20, 2010 in New York City.

 

What:

Teva Presentation at the UBS Global Life Sciences Conference in New York City
 

Who:

William Marth, President & CEO, Teva Pharmaceuticals – Americas
 

When:

Monday, September 20, 2010 at 2:30pm (ET)
 

Where:

http://cc.talkpoint.com/ubsx001/092110a_lv/?entity=12_T81BWOT or http://www.tevapharm.com/financial/

 

How:

Live over the Internet -- log onto the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs more than 40,000 people around the world and reached $13.9 billion in net sales in 2009.



CONTACT:

Investor Relations:
Teva Pharmaceutical Industries Ltd.
Elana Holzman, 972 (3) 926-7554
or
Teva North America
Kevin Mannix, 215-591-8912
or
Media:
Teva Pharmaceutical Industries Ltd.
Yossi Koren, 972 (3) 926-7590
or
Teva North America
Denise Bradley, 215-591-8974

KEYWORDS:   United States  North America  New York  Middle East  Israel

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Suggested Articles

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

Data on Roche's Polivy aren't yet enough to win support from England's cost watchdogs, who rejected the medicine based on long-term…